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Abstract
Background:  Clinical trial and epidemiological studies need high quality biospecimens from a
representative sample of participants to investigate genetic influences on treatment response and disease.
Obtaining blood biospecimens presents logistical and financial challenges. As a result, saliva biospecimen
collection is becoming more frequent because of the ease of collection and lower cost. This article
describes an assessment of saliva biospecimen samples collected through the mail, trial participant
demographic and behavioral characteristics, and their association with saliva and DNA quantity and quality.
Methods:  Saliva biospecimens were collected using the Oragene® DNA Self-Collection Kits from
participants in a National Cancer Institute funded smoking cessation trial. Saliva biospecimens from 565
individuals were visually inspected for clarity prior to and after DNA extraction. DNA samples were then
quantified by UV absorbance, PicoGreen®, and qPCR. Genotyping was performed on 11 SNPs using
TaqMan® SNP assays and two VNTR assays. Univariate, correlation, and analysis of variance analyses were
conducted to observe the relationship between saliva sample and participant characteristics.
Results: The biospecimen kit return rate was 58.5% among those invited to participate (n = 967) and
47.1% among all possible COMPASS participants (n = 1202). Significant gender differences were observed
with males providing larger saliva volume (4.7 vs. 4.5 ml, p = 0.019), samples that were more likely to be
judged as cloudy (39.5% vs. 24.9%, p < 0.001), and samples with greater DNA yield as measured by UV
(190.0 vs. 138.5, p = 0.002), but reduced % human DNA content (73.2 vs. 77.6 p = 0.005) than females.
Other participant characteristics (age, self-identified ethnicity, baseline cigarettes per day) were associated
with saliva clarity. Saliva volume and saliva and DNA clarity were positively correlated with total DNA yield
by all three quantification measurements (all r > 0.21, P < 0.001), but negatively correlated with % human
DNA content (saliva volume r = -0.148 and all P < 0.010). Genotyping completion rate was not influenced
by saliva or DNA clarity.
Conclusion: Findings from this study show that demographic and behavioral characteristics of smoking
cessation trial participants have significant associations with saliva and DNA metrics, but not with the
performance of TaqMan® SNP or VNTR genotyping assays.
Trial registration: COMPASS; registered as NCT00301145 at clinicaltrials.gov.
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Background
Clinical trial and epidemiological studies need high qual-
ity biospecimens from a representative sample of partici-
pants to investigate genetic influences on treatment
response and disease. DNA is typically extracted from one
of several possible tissue sources including buccal cells,
saliva, and blood, using a number of different methods
[1]. Whole blood generally yields large amounts of high
quality DNA but whole blood collection has limitations
such as the logistics and expense of arranging for phlebot-
omy, lower response rates due to the invasiveness of the
procedure, and time and temperature sensitive shipping
and storage requirements [2]. In light of these limitations,
clinical trials and epidemiological studies are increasingly
using saliva as a source of human DNA because saliva can
be non-invasively collected, sent through the mail, and
stored at room temperature for years before extraction
[3,4]. Response rates associated with salivary biospecimen
collection have been shown to be higher than with whole
blood [5]. Studies have shown that saliva collected from
Oragene® DNA Self-Collection Kits (DNA Genotek, Inc.,
Ottawa, Ontario, Canada), as well as other methods, yield
high quality DNA, that can be used as an alternative to
DNA extracted from blood [4-9].
One potential limitation associated with the use of saliva
DNA is the potential effect of variable percentages of
human and non-human DNA on various DNA quantifica-
tion and genotyping methods. The most commonly used
DNA quantification methods, such as ultraviolet spectro-
photometric absorbance ("UV") and fluorescent dyes
such as PicoGreen® ("PG") do not differentiate between
human and non-human DNA, but quantitative real time
Polymerase Chain Reaction ("qPCR") or hybridization
methods using human specific oligonucleotide primers
are human DNA specific [10-13]. In one study, an esti-
mate of the fraction of human DNA in DNA extracted
from saliva ranged from 11-100% [9]. Two studies have
shown increased amounts of specific types of bacteria in
saliva of smokers compared to that of nonsmokers
[14,15]. A study evaluating the effects of the fraction of
human DNA present in DNA extracted from saliva and
buccal samples on genotyping using the Affymetrix Gene-
Chip® Mapping 500K Array suggested that samples con-
taining < 30% human DNA had poor genotyping
performance [16].
Because biospecimens are an essential component for
clinical biomarker or genetic epidemiological studies, any
demographic, behavioral, processing, or quantification
factors that could impact the quality or suitability of
biospecimens for molecular analysis should be investi-
gated. The purpose of this report is to investigate associa-
tions of smoking cessation trial participant demographic
and behavioral variables with saliva and saliva DNA char-
acteristics, including saliva volume, saliva and DNA visual
clarity, total DNA yield, and human DNA concentration,
as well as the relationship between saliva characteristics
and total and human DNA concentrations and genotyp-
ing performance.
Methods
Participants and saliva collection
All recruitment, consent, screening and data collection
methods were reviewed and approved by the Institutional
Review Boards of SRI International (SRI) and Group
Health (GH). Participants were recruited from the Com-
prehensive Medication Program And Support Services
(COMPASS) study, a randomized trial sponsored by the
National Cancer Institute (NCT00301145) that recruited
participants from members of Group Health (GH), a large
health care system in Washington state. COMPASS was
designed to compare the effectiveness of three versions of
a smoking cessation behavioral therapy combined with
Chantix® (varenicline tartrate, Pfizer) [Swan GE, McClure
JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, Deprey M,
Richards J, McAfee TA: Behavioral Counseling and Varen-
icline Treatment for Smoking Cessation. American Jour-
nal of Preventive Medicine (submitted)]. COMPASS
participants were invited by telephone to provide a saliva
sample for a National Institute of Drug Abuse sponsored
study being conducted by the Pharmacogenetics of Nico-
tine Addiction and Treatment (PNAT) consortium http://
www.pharmgkb.org/contributors/pgrn/pnat_profile.jsp.
Those who agreed to participate were mailed a consent
form and an Oragene® DNA Self-Collection Kit (disk for-
mat OG-250, DNA Genotek, Ottawa, Ontario, Canada).
Participants were instructed to follow the manufacturer's
instructions for saliva collection which were to 1) rinse
the mouth with drinking water and wait at least five min-
utes before spitting saliva into the container; 2) spit
enough saliva to reach an indicated level on the container;
3) screw the container cap on securely and then shake the
container for at least 10 seconds. Samples were mailed
back to the lab at room temperature, and participants
were paid $25 upon sample receipt. If there was evidence
of low yield or low DNA quality after DNA extraction,
quantification and genotyping, participants were re-con-
tacted and asked to provide a second sample. Additional
written instructions to refrain from eating 30 minutes
before saliva collection was added to the second mailed
kits to help prevent any carryover of food particles.
DNA extraction
Saliva was stored at room temperature for up to 7 months
in the Oragene® disks until DNA extraction. According to
the manufacturer of the disks, saliva DNA is stable for over
2 years at room temperature [3]. Prior to DNA extraction,
saliva samples were visually inspected and rated as "clear"
or "cloudy" by the same laboratory analyst, as there wereBMC Medical Research Methodology 2009, 9:71 http://www.biomedcentral.com/1471-2288/9/71
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some samples with notable phlegm or cloudiness. DNA
was extracted from saliva samples using the manufac-
turer's protocol for manual purification of DNA from 4.0
mL, PD-PR-015 Issue 2.0. The entire saliva sample was
extracted with reagent volumes adjusted to maximize the
amount of DNA recovered. Briefly, samples were mixed
by inversion, and then incubated overnight at 50°C. Sam-
ples were transferred to a centrifuge tube and mixed with
Oragene® purifier, incubated on ice, then centrifuged at
either 2500 × g or 3000 × g (protocol versions 1 or 2,
respectively) for 20 minutes to pellet the denatured pro-
tein. The supernatant was transferred to a new tube and
DNA was precipitated by adding an equal volume of
100% ethanol. The DNA pellet was washed with 70% eth-
anol, dried, and resuspended with DNA hydration solu-
tion (Qiagen, Valencia, CA). DNA was incubated at 50°C
for 1 hour, followed by incubation at room temperature
overnight to ensure complete rehydration. A high speed
centrifugation step at 15,000 × g was performed to remove
additional impurities. DNA samples were also rated as
"clear" or "cloudy" by the same laboratory analyst via vis-
ual inspection of the tube when held up against a black
background and compared to a referent tube that was pre-
viously noted as cloudy. DNA samples were stored at 4°C
for up to 3 days until quantification.
DNA quantification
DNA samples were quantified using three methods - UV,
PG and qPCR. UV absorbance was measured via the Nan-
odrop Technologies NanoDrop® ND-1000 Spectropho-
tometer (Wilmington, DE) and software. Genotyping was
done on dilutions based on UV concentrations. A portion
of the dilution tubes were rechecked via UV, and then sub-
sequently quantified with two additional different quan-
tification methods. For PG, double stranded DNA
concentration was assessed using Quant-iT™ PicoGreen®
dsDNA Reagent (Invitrogen™, Carlsbad, CA) on a Tecan
GENios™ (San Jose, CA) spectrophotometer. Human
nuclear DNA concentration was assessed by an intra-Alu-
based quantitative PCR (qPCR) assay in a singleplex PCR
of 25 ul and otherwise as described [13]. Samples were
amplified with a standard curve and three no-DNA tem-
plate controls on each plate. The standard curve, per-
formed in duplicate, ranged from 100 ng to 0.01 ng per
well for each qPCR plate using lymphoblastoid cell line
DNA NA07019 (Coriell Cell Repositories, Camden, New
Jersey). qPCR reactions were analyzed using SDS v.1.2.3
software (Applied Biosystems), with manual baseline call-
ing. DNA yield was estimated by measured concentration
× dilution factor × the total resuspension volume. An esti-
mate of the fraction of human DNA in saliva DNA was
obtained by dividing the qPCR measurement by the PG
measurement.
Genotyping
Genotyping was performed on all DNA samples for 11
TaqMan® single nucleotide polymorphism (SNP) assays
(Applied Biosystems) and for two variable number of tan-
dem repeat (VNTR) polymorphisms. Positive controls for
each TaqMan® cluster group and no DNA template con-
trols were included on each plate using the suggested pro-
tocol [17]. To evaluate discordance, 10% of the samples
were genotyped in duplicate, as was the second saliva
DNA sample collected for 18 participants. TaqMan® assays
were analyzed using SDS v1.2.3 software. Other genotyp-
ing assays were performed for VNTRs in the 3'UTR of
SLC6A3 [18] and in Exon 3 of DRD4 [19].
Statistical analysis
Univariate, correlation and analysis of variance analyses
were performed using SAS version 9.1 (Cary, NC). Tests of
statistical significance used a Type I error rate of 0.05.
Results
Saliva sample collection and participant demographic and 
behavioral characteristics
Of the total of 1,202 participants randomized to treat-
ment in the COMPASS study [Swan GE, McClure JB, Jack
LM, Zbikowski SM, Javitz HS, Catz SL, Deprey M, Richards
J, McAfee TA: Behavioral Counseling and Varenicline
Treatment for Smoking Cessation. American Journal of
Preventive Medicine (submitted)], a total of 1,101 were
eligible for this PNAT study (see Figure 1). Successful con-
tact was made with 967 participants (87.8% of those eli-
gible) and a total of 566 participants (58.5% of those
contacted and 51.4% of those eligible) returned saliva
kits. One kit received was empty, resulting in usable saliva
samples from 565 participants. The overall participant
characteristics can be seen in Table 1. There were no sig-
nificant differences between the N = 566 COMPASS par-
ticipants who returned a saliva collection kit (47.1%) and
the N = 636 (1202-566) other participants with respect to
gender, ethnicity (self identified non-Hispanic Cauca-
sian), years of formal schooling, and amount smoked.
Those who did return a saliva collection kit were signifi-
cantly older than those who did not (48.1 vs. 45.0 years, t
= -5.2, p < .0001).
After DNA extraction, quantification and genotyping, 38
participants were recontacted to request a second saliva
sample due to evidence of low yield (n = 15) or low initial
genotyping rate (n = 23) when 3 or more out of 7 initial
TaqMan® assays tested had failed. Half of the attempted
requests for a second saliva sample (n = 19) resulted in a
kit being returned, one of which was empty. There were
no significant differences in age, gender, ethnicity, years of
formal schooling or amount smoked between those who
provided two samples compared to those who provided
one. In all cases but two the second sample appearedBMC Medical Research Methodology 2009, 9:71 http://www.biomedcentral.com/1471-2288/9/71
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superior with respect to genotyping completion rate and
was used instead of the first sample (i.e., only one sample
was used per person), resulting in a total of 565 samples
for analysis. In addition, for the 7 usable samples that had
a second sample returned because of an initial low yield,
6 gave similar low yields (data not shown).
Saliva sample and saliva DNA characteristics
The overall saliva and saliva DNA characteristics can be
seen in Table 1. DNA analysis (N = 539) was limited to
one sample per participant for which all three quantifica-
tion measurements were available. Total DNA yield meas-
urements were all highly significantly correlated
(Spearman) (UV vs PG (r = 0.922, P < 0.001), UV vs qPCR
(r = 0.832, P < 0.001), and PG vs qPCR (r = 0.962, P <
0.001)) (Figure 2) and saliva volume was significantly
correlated with the total DNA yield as measured by each
of the three methods using UV, PG, and qPCR (r = 0.33,
0.28, 0.25 respectively, all P < 0.001), but inversely corre-
lated with the calculated % human DNA (r = -0.148, P =
0.005). A median of 77%, a mean (SD) of 76.1%
(17.1%), and a range of 2.4-159% estimated human DNA
content was obtained (Figure 3). The single sample at
159% was excluded from the figure, but not from analysis.
For the sample concentrations for all three quantification
methods see Additional file 1.
Participant and saliva or saliva DNA associations
When the time between kit receipt and extraction is split
at the median (≤ 55 days = "Early Extraction" and ≥ 56
days = "Later Extraction"), there were no significant differ-
ences for the three DNA yield measurements or for geno-
typing completion rate (data not shown). The same was
true when a linear model was applied (data not shown).
The mean (SD) A260/280 for the earlier extractions vs.
later extractions was 1.82 (0.10) and 1.86 (0.11), t(537) = -
4.28, P < 0.001 respectively, and although significantly
different, both were in an acceptable range. When a linear
model was applied, the A260/A280 remained significant
(r = 0.24, P < 0.01).
There were statistically significant associations between
participant demographic and behavioral characteristics
and saliva and DNA volume, clarity, and yield (Tables 2
and 3). Females provided significantly less saliva and had
significantly lower total DNA yield by UV but significantly
higher % human DNA yields, and provided saliva which
was clear significantly more often than did males. Non-
Hispanic Caucasians provided significantly more saliva,
which was cloudy significantly more often and which
resulted in significantly more total DNA yield by UV, than
all others. Age was significantly associated with reduced
saliva clarity and reduced % human DNA yield. CPD were
Table 1: COMPASS participant and sample characteristics
Characteristic M (SD) or % Range
Participants (n = 566)
Age (years) 49.1 (11.4) 19.0-76.8
Gender (% female) 67.8
Ethnicity (% NHC) 88.5
Years of formal schooling 14.2 (2.2) 6.0-24.0
Cigarettes per day (CPD) 20.1 (8.2) 4.0-80.0
Saliva (n = 565)
Time between kit receipt and DNA extraction (days) 63.8 (43.1) 2.0-203.0
Volume (ml) 4.5 (1.1) 1.0-7.5†
Visual clarity (% "cloudy") 29.6
DNA (n = 539)
Processed with protocol 2 (%) 80.0
DNA yield by UV (ug) 155.2 (156.1) 1.5-1153.3
DNA yield by PG (ug) 82.8 (79.4) 0.9-549.3
DNA yield by qPCR (ug) 61.5 (58.6) 0.8-344.3
Visual clarity (% "cloudy") 17.2
A260/280 1.83 (0.10) 1.42-2.13
†An 8.5 ml sample was also included that was derived from two saliva kits extracted together. The range shown in Table 1 show saliva volumes 
from single saliva collection kits.BMC Medical Research Methodology 2009, 9:71 http://www.biomedcentral.com/1471-2288/9/71
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significantly associated with increased saliva volume and
with saliva that was clear significantly less often.
Among saliva and saliva DNA samples judged to be
cloudy (Table 4), saliva volumes were significantly
increased and DNA yields were increased to approxi-
mately twice that of clear samples, while estimated %
human DNA was reduced to approximately 92% of clear
samples. DNA purity (A260/280 ratio) and genotyping
completion rate were not significantly associated with
saliva or saliva DNA sample clarity. The DNA extraction
protocol version that used higher centrifuge speeds
showed no significant differences in DNA yield, DNA clar-
ity, or genotyping success rate (data not shown). The gen-
otyping completion rate for each SNP assay tested was
over 98% per subject and for the SLC6A3  and  DRD4
VNTRs were 98.5% and 97.5% per subject. All genotype
distributions were in Hardy Weinberg Equilibrium and no
genotype discordance was found when re-genotyping
10% of the samples or when comparing called genotypes
from the initial saliva sample to the second saliva sample
collected from 18 participants. Out of the 14 second saliva
samples received from individuals recontacted because of
poor genotyping completion rates, 12 had improved gen-
otyping rates and 2 did not. The mass of human DNA
added to genotyping reactions was not associated with
Saliva biospecimen collection from COMPASS participants Figure 1
Saliva biospecimen collection from COMPASS participants.BMC Medical Research Methodology 2009, 9:71 http://www.biomedcentral.com/1471-2288/9/71
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TaqMan® genotype completion rate (Pearson r = 0.064, P
= 0.122), but was significantly associated with VNTR gen-
otype completion rate (Pearson r = 0.173, P < 0.001).
Discussion
In this study we observed significant influences of demo-
graphic and behavioral characteristics on saliva and DNA
quantity and quality as well as significant associations
among saliva biospecimen and DNA characteristics. Gen-
der and ethnicity exhibited associations with saliva vol-
ume and DNA quantities, similar to a study that collected
buccal cells by a mouthwash method where males had
greater buccal DNA yields (quantified by UV) than
females [20]. A recent study suggested a relationship
between genetic relatedness of participants and the qual-
ity of the DNA prepared from their saliva [12], although is
unclear if this is from potentially heritable biological or
environmental factors that inhibit PCR.
Saliva volumes were significantly inversely associated
with saliva biospecimen clarity and saliva DNA clarity.
Although saliva and saliva DNA biospecimen samples
judged to be "cloudy" tended to have increased total DNA
yield and decreased % human DNA, they had similar gen-
otyping success rates and A260/280 ratios as "clear" sam-
ples. The timing of DNA extraction was not related to total
DNA yield or genotyping performance, which is consist-
ent with DNA Genotek's report that the saliva samples are
stable at room temperature and yield high quality DNA
[3].
The estimated human DNA content of DNA extracted
from COMPASS saliva samples (median, 77%) is similar
to previously reported results for DNA extracted from
saliva biospecimens collected using Oragene® kits, where
median human DNA content has been reported to be
68% and 80% using prothrombin and RNaseP qPCR
assays, respectively [9,21] and is higher than that reported
for other oral-cavity related biospecimen samples such as
cytobrush (11.5%) and mouthwash samples (49.5%)
[10]. This may be due to the antibacterial reagents in the
Oragene kits that prevent bacterial growth. We obtained
some values greater than 100% for estimated % human
DNA content, which may be explained by our use of a
Total DNA yield measured by PicoGreen® vs human DNA yield measured by qPCR, and vs total DNA yield measured by UV,  N = 539 COMPASS saliva DNA samples Figure 2
Total DNA yield measured by PicoGreen® vs human DNA yield measured by qPCR, and vs total DNA yield 
measured by UV, N = 539 COMPASS saliva DNA samples.BMC Medical Research Methodology 2009, 9:71 http://www.biomedcentral.com/1471-2288/9/71
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ratio of two different quantification methods, each with
substantial variance.
The genotyping completion rate for all SNP and VNTR
genotyping assays was over 97%. These genotyping rates
are similar to or higher than previously reported genotyp-
ing completion rates for DNA extracted from saliva sam-
ples using the same saliva collection kit [12,22]. In
addition, the genotyping completion rate was substan-
tially higher for our samples collected using the Oragene
kit (98.5%) vs. a mailed buccal swab method (68%) for
the same SLC6A3  VNTR polymorphism [18]. Previous
reports have suggested some relationship with genotyping
success and the amount of human DNA [12,16,22].
Although we did not observe a significant association
between % human DNA and TaqMan® SNP assay per-
formance, more studies should be done to assess this rela-
tionship with other high throughput genotyping or
sequencing platforms.
Limitations
Saliva and DNA clarity observations did not use previ-
ously established validated protocols. For this study,
although all clarity determinations were made by a single
observer, there was no confirmation by a second observer.
A limitation to the human DNA quantification method
using a qPCR assay is that it may be sensitive to unknown
PCR inhibitors present in greater concentration in the
cloudy samples. Participants who had more total DNA as
measured by PG also had more human DNA as measured
by qPCR, even though the percent of human DNA
decreased. As DNA yields from most samples with the rec-
ommended saliva volumes are adequate for genotyping,
encouraging compliance with the saliva protocol to col-
lect the recommended amount of saliva, and no more, is
recommended.
Studies collecting biospecimen samples through the mail
have variable return rates, and low biospecimen return
rates could be a limitation. A study utilizing a different
saliva collection procedure through the mail had an 80%
return rate recruiting from a smoking cessation website
[23], while another study using a mouthwash protocol
through the mail had a 37% return rate from a cohort of
smokers selected from participants of a smoking cessation
intervention [24]. A study collecting cigarette smoking
survey data and genetic material via buccal cell sampling
through the mail had 25% of their total interviewees, rep-
% human DNA for N = 538 COMPASS saliva DNA samples Figure 3
% human DNA for N = 538 COMPASS saliva DNA samples.
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resenting 45% of those who agreed to receive a buccal cell
collection kit, actually return their buccal cell kits [25].
With these reported percentages only representing a sub-
set of the whole study, it is important to show that the
biospecimens being analyzed were obtained from a repre-
sentative sample of the whole study, or to find ways to
improve participation in genetic aspects of population or
clinically based studies. Having genetic material from a
subset of all participants in a study could be a limitation
and could potentially bias genetic association results. In
our study, those who returned a kit were significantly
older than those who did not, and this difference in age
should be acknowledged when generalizing genetic asso-
ciation results to the entire COMPASS sample. Other lim-
itations to collecting saliva samples in the mail include
the inability to confirm compliance with collection proto-
cols and to confirm that the biospecimen donor is the trial
participant.
Table 2: Saliva and saliva DNA quantity by COMPASS participant characteristics
Saliva Volume DNA Yield UV % Human DNA
N = 565 samples N = 539 samples N = 539 samples
Overall mean (SD) 4.5 (1.1) 155.2 (156.1) 76.1 (17.1)
Correlations
Age
R value 0.02 0.05 -0.10
P value 0.684 0.270 0.027
CPD*
R value 0.10 0.03 -0.02
P value 0.016 0.448 0.719
Average by category
Gender
Female 4.5 (1.1) 138.5 (132.4) 77.6 (16.8)
Male 4.7 (1.1) 190.0 (192.3) 73.2 (17.2)
P value 0.019 0.002 0.005
Ethnicity
Other 4.3 (1.0) 122.0 (128.5) 76.7 (18.8)
NHC† 4.6 (1.1) 159.3 (159.0) 76.0 (16.8)
P value 0.042 0.040 0.758
*CPD = cigarettes per day. †NHC = non-Hispanic Caucasian.
Table 3: Saliva and DNA clarity by COMPASS participant characteristics
Saliva Clarity
(N = 533 samples)
DNA Clarity
(N = 539 samples)
Clear Cloudy P-value Clear Cloudy P-value
Age, mean (SD), y 48.1 (11.4) 51.1 (11.0) 0.005 48.9 (11.4) 49.4 (11.7) 0.733
CPD, mean (SD) 19.0 (7.0) 22.2 (9.1) <0.001 19.7 (7.4) 21.2 (9.4) 0.143
Gender
Female 75.1% 24.9% <0.001 84.9% 15.1% 0.057
Male 60.5% 39.5% 78.3% 21.7%
Ethnicity
Other 85.0% 15.0% 0.008 87.1% 12.9% 0.351
NHC 68.4% 31.6% 82.4% 17.6%BMC Medical Research Methodology 2009, 9:71 http://www.biomedcentral.com/1471-2288/9/71
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With numerous methods to quantify DNA, human spe-
cific DNA quantification may be the most useful for spe-
cific biospecimen types such as saliva and buccal swabs
that can contain other non-human or biological contam-
inants. Although saliva and saliva DNA clarity did not
seem to affect the observed genotyping call rate in this
study, it is unclear to what degree these variables may
affect different quantification methods which may affect
input DNA mass and genotyping performance for other
genotyping technologies.
Conclusion
Findings from this study show that demographic and
behavioral characteristics of smoking cessation trial par-
ticipants have significant associations with saliva and
DNA metrics. Potential saliva donors should be encour-
aged to provide the recommended amount of saliva, but
no more than the recommended amount. Although some
participant characteristics are associated with DNA quan-
tity and clarity, the saliva collection process yields an
amount of DNA sufficient for genotyping in most samples
using TaqMan® SNP and VNTR genotyping assays. Saliva
samples collected through the mail can provide high qual-
ity DNA for genotyping and allow for easier biospecimen
collection which can possibly increase study participa-
tion.
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Table 4: Saliva and saliva DNA yield, purity and genotyping rate by sample clarity, COMPASS participants
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Sample variable Clear Cloudy P* Clear Cloudy P*
N samples 375 158 446 93
Saliva volume mean (SD), ml
4.5 (1.1) 4.7 (1.1) 0.037 4.4 (1.0) 5.2 (1.0) <0.001
DNA based measurements mean (SD)
UV, mean (SD), ug 121.7 (111.5) 236.4 (210.5) <0.001 120.2 (104.2) 323.0 (235.8) <0.001
PG, mean (SD), ug 69.3 (62.9) 115.6 (102.6) <0.001 64.2 (55.5) 171.8 (111.0) <0.001
qPCR, mean (SD), ug 54.1 (51.2) 79.4 (70.1) <0.001 49.1 (44.5) 121.4 (78.3) <0.001
A260/280 1.84 (0.10) 1.84 (0.12) 0.746 1.84 (0.11) 1.83 (0.11) 0.617
% human DNA 78.0 (16.4) 71.3 (17.6) <0.001 77.0 (16.9) 72.0 (17.4) 0.010
Genotype (%) 98.5 (9.6) 98.7 (7.4) 0.757 98.4 (9.7) 99.4 (4.0) 0.104
*t test PPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Research Methodology 2009, 9:71 http://www.biomedcentral.com/1471-2288/9/71
Page 10 of 10
(page number not for citation purposes)
References
1. Landi MT, Caporaso N: Sample collection, processing and stor-
age.  IARC Sci Publ 1997:223-236.
2. Vaught JB: Blood collection, shipment, processing, and stor-
age.  Cancer Epidemiol Biomarkers Prev 2006, 15(9):1582-1584.
3. Iwasiow RM, Desbois A, Birnboim HC: Long-term stability of
DNA from saliva samples stored in Oragene®DNA.  Ottawa,
Ontario, Canada: DNA Genotek, Inc; 2004. 
4. Ng DP, Koh D, Choo S, Chia KS: Saliva as a viable alternative
source of human genomic DNA in genetic epidemiology.  Clin
Chim Acta 2006, 367(1-2):81-85.
5. Hansen TV, Simonsen MK, Nielsen FC, Hundrup YA: Collection of
blood, saliva, and buccal cell samples in a pilot study on the
Danish nurse cohort: comparison of the response rate and
quality of genomic DNA.  Cancer Epidemiol Biomarkers Prev 2007,
16(10):2072-2076.
6. Quinque D, Kittler R, Kayser M, Stoneking M, Nasidze I: Evaluation
of saliva as a source of human DNA for population and asso-
ciation studies.  Anal Biochem 2006, 353:272-277.
7. Reynolds JD, Do TT, Hongo DB, Kuramoto IK, Biggs WH III, French
CK:  Comparison of high density genotyping results from
saliva and blood samples on Affymetrix GeneChip® Genom-
eWide SNP 6.0 arrays.  West Sacramento, CA: Affymetrix Clinical
Services Laboratory, Affymetrix, Inc; 2007. 
8. Rogers NL, Cole SA, Lan HC, Crossa A, Demerath EW: New saliva
DNA collection method compared to buccal cell collection
techniques for epidemiological studies.  Am J Hum Biol 2007,
19:319-326.
9. Rylander-Rudqvist T, Hakansson N, Tybring G, Wolk A: Quality and
quantity of saliva DNA obtained from the self-administrated
oragene method--a pilot study on the cohort of Swedish
men.  Cancer Epidemiol Biomarkers Prev 2006, 15(9):1742-1745.
10. Garcia-Closas M, Egan KM, Abruzzo J, Newcomb PA, Titus-Ernstoff
L, Franklin T, Bender PK, Beck JC, Le Marchand L, Lum A, Alavanja M,
Hayes RB, Rutter J, Buetow K, Brinton LA, Rothman N: Collection
of genomic DNA from adults in epidemiological studies by
buccal cytobrush and mouthwash.  Cancer Epidemiol Biomarkers
Prev 2001, 10(6):687-696.
11. Garcia-Closas M, Moore LE, Rabkin CS, Franklin T, Struewing J, Gin-
zinger D, Alguacil J, Rothman N: Quantitation of DNA in buccal
cell samples collected in epidemiological studies.  Biomarkers
2006, 11:472-479.
12. Philibert RA, Zadorozhnyaya O, Beach SR, Brody GH: Comparison
of the genotyping results using DNA obtained from blood
and saliva.  Psychiatr Genet 2008, 18:275-281.
13. Walker JA, Hedges DJ, Perodeau BP, Landry KE, Stoilova N, Laborde
ME, Shewale J, Sinha SK, Batzer MA: Multiplex polymerase chain
reaction for simultaneous quantitation of human nuclear,
mitochondrial, and male Y-chromosome DNA: application
in human identification.  Anal Biochem 2005, 337:89-97.
14. Heintze U: Secretion rate, buffer effect and number of lacto-
bacilli and Streptococcus mutans of whole saliva of cigarette
smokers and nonsmokers.  Scand J Dent Res 1984, 92:294-301.
15. Parvinen T: Stimulated salivary flow rate, pH and lactobacillus
and yeast concentrations in non-smokers and smokers.  Scand
J Dent Res 1984, 92:315-318.
16. Herraez DL, Stoneking M: High fractions of exogenous DNA in
human buccal samples reduce the quality of large-scale gen-
otyping.  Anal Biochem 2008, 383:329-331.
17. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA:
New generation pharmacogenomic tools: a SNP linkage dis-
equilibrium Map, validated SNP assay resource, and high-
throughput instrumentation system for large-scale genetic
studies.  Biotechniques 2002:48-50.
18. Vandenbergh DJ, Bennett CJ, Grant MD, Strasser AA, O'Connor R,
Stauffer RL, Vogler GP, Kozlowski LT: Smoking status and the
human dopamine transporter variable number of tandem
repeats (VNTR) polymorphism: failure to replicate and find-
ing that never-smokers may be different.  Nicotine Tob Res 2002,
4:333-340.
19. George SR, Cheng R, Nguyen T, Israel Y, O'Dowd BF: Polymor-
phisms of the D4 dopamine receptor alleles in chronic alco-
holism.  Biochem Biophys Res Commun 1993, 196:107-114.
20. Le Marchand L, Lum-Jones A, Saltzman B, Visaya V, Nomura AM,
Kolonel LN: Feasibility of collecting buccal cell DNA by mail
in a cohort study.  Cancer Epidemiol Biomarkers Prev 2001,
10(6):701-703.
21. James C, Iwasiow RM, Birnboim HC: Human Genomic DNA Con-
tent of Saliva Samples Collected in Oragene®DNA.  Ottawa,
Ontario, Canada: DNA Genotek, Inc; 2008. 
22. Hansen HM, Wiemels JL, Wrensch M, Wiencke JK: DNA quantifi-
cation of whole genome amplified samples for genotyping on
a multiplexed bead array platform.  Cancer Epidemiol Biomarkers
Prev 2007, 16(8):1686-1690.
23. Etter JF, Neidhart E, Bertrand S, Malafosse A, Bertrand D: Collecting
saliva by mail for genetic and cotinine analyses in partici-
pants recruited through the Internet.  Eur J Epidemiol 2005,
20:833-838.
24. Bauer JE, Rezaishiraz H, Head K, Cowell J, Bepler G, Aiken M, Cum-
mings KM, Hyland A: Obtaining DNA from a geographically dis-
persed cohort of current and former smokers: use of mail-
based mouthwash collection and monetary incentives.  Nico-
tine Tob Res 2004, 6:439-446.
25. Kozlowski LT, Vogler GP, Vandenbergh DJ, Strasser AA, O'Connor
RJ, Yost BA: Using a telephone survey to acquire genetic and
behavioral data related to cigarette smoking in "made-anon-
ymous" and "registry" samples.  Am J Epidemiol 2002, 156:68-77.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2288/9/71/prepub